New strategy for renal cancer therapy
Wed Apr 06 12:22:45 CEST 2022
Event date:
Wed Apr 06 12:22:45 CEST 2022 | Wed Apr 06 12:22:45 CEST 2022 - Wed Apr 06 12:22:45 CEST 2022
Wed Apr 06 12:22:45 CEST 2022 | Wed Apr 06 12:22:45 CEST 2022 - Wed Apr 06 12:22:45 CEST 2022
A research team led by Professor Jiří Neužil from the Institute of Biotechnology of the Academy of Sciences of the Czech Republic at the BIOCEV center described the effect of the Czech anti-cancer substance MitoTam in combination with immunotherapy on kidney tumors.
The paper follows the recently completed first phase of the clinical trial of the substance. The greatest benefit was shown in patients with kidney cancer. In one case, the kidney tumor was reduced up to 30 times. The findings will be used in the design of the second phase of clinical trials, which could begin next year.
Read the whole article HERE
